ERBB2 and breast cancer: However, PPS IB remains heterogeneous and includes a wide range of patients from locally advanced anatomic pathologic stage IIIA/B (pT3N1 or pT1-3N2, G1–2) HR-positive/HER2-negative BC (LA-HR+/HER2- BC) to those with early-stage anatomic pathologic stage IA (T1N0, G2–3) triple-negative BC (ES-TNBC).